The association between obesity and gynecological cancer

Gynecology and Minimally Invasive Therapy

Volumn 4, Issue 4, 2015, Pages 102-105

  Feng, Yin Hsun ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Gynecological cancer; Metabolic syndrome; Obesity

Indexed keywords

ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; CARBOPLATIN; ESTRONE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; SOMATOMEDIN; TAMOXIFEN;

ADIPOSE TISSUE; BODY MASS; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE GENITAL TRACT CANCER; HUMAN; HYSTERECTOMY; MAMMOGRAPHY; MOLECULAR PATHOLOGY; OBESITY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL MORTALITY; SURVIVAL RATE; UTERINE CERVIX CANCER;

EID: 84959323713     PISSN: 22133070     EISSN: 22133089     Source Type: Journal    
DOI: 10.1016/j.gmit.2015.03.003     Document Type: Review

References (57)

1. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
2. Akiyama T., Yoneda M., Maeda S., Nakajima A., Koyama S., Inamori M. Visceral obesity and the risk of Barrett's esophagus. Digestion 2011, 83:142-145.
3. Adams K.F., Leitzmann M.F., Albanes D., et al. Body mass and colorectal cancer risk in the NIH-AARP cohort. Am J Epidemiol 2007, 166:36-45.
4. Slattery M.L., Potter J., Caan B., et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 1997, 57:75-80.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
6. Cui Y., Whiteman M.K., Flaws J.A., Langenberg P., Tkaczuk K.H., Bush T.L. Body mass and stage of breast cancer at diagnosis. Int J Cancer 2002, 98:279-283.
7. Griggs J.J., Sorbero M.E., Lyman G.H. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005, 165:1267-1273.
8. Okwan-Duodu D., Umpierrez G.E., Brawley O.W., Diaz R. Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res 2013, 3:21-33.
9. Pisani P., Parkin D.M., Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993, 55:891-903.
10. Bergstrom A., Pisani P., Tenet V., Wolk A., Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001, 91:421-430.
11. Emons G., Fleckenstein G., Hinney B., Huschmand A., Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000, 7:227-242.
12. Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000, 13:295-308.
13. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10-17.
14. Flier J.S. Insulin receptors and insulin resistance. Annu Rev Med 1983, 34:145-160.
15. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106.
16. Troisi R., Potischman N., Hoover R.N., Siiteri P., Brinton L.A. Insulin and endometrial cancer. Am J Epidemiol 1997, 146:476-482.
17. Talavera F., Reynolds R.K., Roberts J.A., Menon K.M. Insulin-like growth factor I receptors in normal and neoplastic human endometrium. Cancer Res 1990, 50:3019-3024.
18. Ayabe T., Tsutsumi O., Sakai H., et al. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997, 44:419-424.
19. Franks S., Kiddy D.S., Hamilton-Fairley D., Bush A., Sharp P.S., Reed M.J. The role of nutrition and insulin in the regulation of sex hormone binding globulin. J Steroid Biochem Mol Biol 1991, 39:835-838.
20. Zhang Q., Shen Q., Celestino J., et al. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 2009, 200:186. e1-8.
21. Nieto-Vazquez I., Fernandez-Veledo S., Kramer D.K., Vila-Bedmar R., Garcia-Guerra L., Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008, 114:183-194.
22. Arem H., Park Y., Pelser C., et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst 2013, 105:342-349.
23. Lino-Silva LS, de Leon DC, Salcedo-Hernandez RA, Cavazos-Saman C, Perez-Montiel MD. A high body mass index is not a worse prognostic factor for endometrial carcinoma in a predominantly obese population. Clin Transl Oncol 15:243-247.
24. Reeves K.W., Carter G.C., Rodabough R.J., et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol Oncol 2011, 121:376-382.
25. Erkanli S., Kayaselcuk F., Bagis T., Kuscu E. Impact of morbid obesity in surgical management of endometrial cancer: surgical morbidity, clinical and pathological aspects. Eur J Gynaecol Oncol 2006, 27:401-404.
26. Everett E., Tamimi H., Greer B., et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003, 90:150-157.
27. Lin L.L., Hertan L., Rengan R., Teo B.K. Effect of body mass index on magnitude of setup errors in patients treated with adjuvant radiotherapy for endometrial cancer with daily image guidance. Int J Radiat Oncol Biol Phys 2012, 83:670-675.
28. Martra F., Kunos C., Gibbons H., et al. Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study. Am J Obstet Gynecol 2008, 198:89. e81-88.
29. Sasieni P.D., Cuzick J., Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996, 73:1001-1005.
30. Lin C.T., Wang C.N., Lai C.H. Immunotherapy for advanced or relapsed cervical cancer. Gynecol Minim Invasive Ther 2013, 2:3-7.
31. Maruthur N.M., Bolen S.D., Brancati F.L., Clark J.M. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obesity (Silver Spring) 2009, 17:375-381.
32. Lacey J.V., Swanson C.A., Brinton L.A., et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003, 98:814-821.
33. Kizer N.T., Thaker P.H., Gao F., et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 2011, 117:948-956.
34. Legge F., Margariti P.A., Lucidi A., et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures. Acta Oncol 2013, 52:166-173.
35. Soisson A.P., Soper J.T., Berchuck A., Dodge R., Clarke-Pearson D. Radical hysterectomy in obese women. Obstet Gynecol 1992, 80:940-943.
36. Frumovitz M., Sun C.C., Jhingran A., et al. Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol 2008, 112:899-905.
37. Australian Institute of Health and Welfare, National Breast and Ovarian Cancer Centre (Australia) Ovarian cancer in Australia: an overview 2010, Australian Institute of Health and Welfare, Canberra.
38. Purdie D.M., Green A.C. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001, 15:341-354.
39. Olsen C.M., Green A.C., Whiteman D.C., Sadeghi S., Kolahdooz F., Webb P.M. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007, 43:690-709.
40. Olsen C.M., Nagle C.M., Whiteman D.C., Purdie D.M., Green A.C., Webb P.M. Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer 2008, 123:450-456.
41. Yang H.S., Yoon C., Myung S.K., Park S.M. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 2011, 21:1525-1532.
42. Skirnisdottir I., Sorbe B. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer 2008, 18:345-351.
43. Fotopoulou C., Richter R., Braicu E.I., et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Ann Surg Oncol 2011, 18:2629-2637.
44. Wright J.D., Tian C., Mutch D.G., et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 109:353-358.
45. Ahn J., Schatzkin A., Lacey J.V., et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007, 167:2091-2102.
46. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059. Collaborative Group on Hormonal Factors in Breast Cancer.
47. Carmichael A.R. Obesity and prognosis of breast cancer. Obes Rev 2006, 7:333-340.
48. Maruthur N.M., Bolen S., Brancati F.L., Clark J.M. Obesity and mammography: a systematic review and meta-analysis. J Gen Intern Med 2009, 24:665-677.
49. John E.M., Sangaramoorthy M., Phipps A.I., Koo J., Horn-Ross P.L. Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. Am J Epidemiol 2011, 173:201-216.
50. Lahmann P.H., Hoffmann K., Allen N., et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004, 111:762-771.
51. Chlebowski R.T., Aiello E., McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002, 20:1128-1143.
52. Haakinson D.J., Leeds S.G., Dueck A.C., et al. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol 2012, 19:3012-3018.
53. Yang X.R., Chang-Claude J., Goode E.L., et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011, 103:250-263.
54. Pierobon M., Frankenfeld C.L. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013, 137:307-314.
55. Dignam J.J., Wieand K., Johnson K.A., Fisher B., Xu L., Mamounas E.P. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003, 95:1467-1476.
56. Bastarrachea J., Hortobagyi G.N., Smith T.L., Kau S.W., Buzdar A.U. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994, 120:18-25.
57. Gennari A., Nanni O., Puntoni M., et al. Body mass index and prognosis of metastatic breast cancer patients receiving first line chemotherapy. Cancer Epidemiol Biomarkers Prev 2013, 22:1862-1867.